Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Blood

• Publication date

  1999-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V93.5.1781.405A39C_1781_1782PMID 10084817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.

  1996cited by this paper
• Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation.

  1995cited by this paper
• Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.

  1994cited by this paper

• Development and Validation of a Liquid Chromatograph-Tandem Mass Spectrometry Method for Quantifying Ganciclovir in Dried Blood Spots for Therapeutic Drug Monitoring.

  2026cites this paper
• Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial

  2025cites this paper
• Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes

  2024cites this paper
• Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review

  2024cites this paper
• Are hematopoietic cell transplant recipients with Gram‐negative bacteremia spending more time outpatient while on intravenous antibiotics? Addressing trends over 10 years at a single center

  2021cites this paper
• Clinical and economic burden of pre‐emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients

  2020cites this paper
• CMV Prevention and Treatment in Transplantation: What’s New in 2019

  2019cites this paper
• Capsule Endoscopy after Hematopoietic Stem Cell Transplantation Can Predict Transplant-Related Mortality

  2019cites this paper
• Prophylaxis and Management of Infectious Complications After Hematopoietic Cell Transplantation

  2019cites this paper
• Burden of cytomegalovirus disease in allogeneic hematopoietic cell transplant recipients: a national, matched cohort study in an inpatient setting.

  2018cites this paper
• Lower gamma globulin level before conditioning is a risk factor for cytomegalovirus antigenemia after pediatric allogeneic stem cell transplantation

  2018cites this paper
• Early abnormal liver enzyme levels may increase the prevalence of human cytomegalovirus antigenaemia after hematopoietic stem cell transplantation

  2017cites this paper
• Risks and Epidemiology of Infections After Hematopoietic Stem Cell Transplantation

  2016cites this paper
• [T cell receptor β-chain CDR3 spectratyping and cytomegalovirus activation in allogeneic hematopoietic stem cell transplant recipients].

  2016cites this paper
• In vitro studies of the impact of maribavir on CMV-specific cellular immune responses.

  2016cites this paper
• Risk factors for ganciclovir-induced thrombocytopenia and leukopenia.

  2015cites this paper
• Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices.

  2015cites this paper
• Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial

  2015cites this paper
• Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation

  2014cites this paper
• The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.

  2014cites this paper
• The Clinical and Financial Burden of Preemptive Management of CMV Disease after Allogeneic Stem Cell Transplantation – Implications for Preventative Treatment Approaches

  2014cites this paper
• lymphoproliferative disorders comparison between 2 prospective studies in patients with Nonmyeloablative transplantation with or without alemtuzumab

  2013cites this paper
• Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group.

  2013cites this paper
• for adoptive transfer into allogeneic stem cell transplant recipients Rapid generation of combined CMV-specific CD4+and CD8+ T-cell lines

  2013cites this paper
• サイトメガロウイルス（CMV）：ウイルス学的特徴と測定方法

  2013cites this paper
• early protection in acute myeloid leukemia CMV reactivation after allogeneic HCT and relapse risk: evidence for

  2013cites this paper
• CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

  2013cites this paper
• Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience.

  2013influential citation
• rebound VZV disease after drug discontinuation disease following hematopoietic cell transplantation: no evidence of One-year acyclovir prophylaxis for preventing varicella-zoster virus (VZV)

  2013cites this paper
• Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation.

  2012cites this paper
• Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus

  2012cites this paper
• Development of two potential diagnostic monoclonal antibodies against human cytomegalovirus glycoprotein B

  2012cites this paper
• Development of two potential diagnostic monoclonal antibodies against human cytomegalovirus glycoprotein B.

  2012cites this paper
• HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation.

  2012cites this paper
• Fatal CMV-Infection after Autologous Stem Cell Transplantation in Refractory Systemic Lupus Erythematosus

  2012cites this paper
• Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.

  2012cites this paper
• Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients

  2012cites this paper
• RECENT ADVANCES IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ( HCT )

  2012cites this paper
• Multiplex polymerase chain reaction for six herpesviruses after hematopoietic stem cell transplantation

  2011cites this paper
• Antiviral Chemoprophylaxis for Ocular Viral Infections in Hematopoietic Stem Cell and Bone Marrow Transplant Patients

  2011cites this paper
• Viral infections in immunocompromised patients

  2011cites this paper
• Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT

  2011cites this paper
• Can the HCMV-pp65-antigenemia assay completely be replaced by HCMV-PCR in monitoring patients after bone marrow transplantation?

  2010cites this paper
• STRATEGIES FOR MANAGEMENT OF EBV AND ADENOVIRUS INFECTIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

  2010cites this paper
• T-cell therapy for cytomegalovirus infection

  2010cites this paper
• Status of hematopoietic stem cell transplantation in the WHO Eastern Mediterranean Region (EMRO).

  2010cites this paper
• Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes

  2010cites this paper
• Reduced mortality after allogeneic hematopoietic-cell transplantation.

  2010cites this paper
• Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.

  2009cites this paper
• prednisone does not compromise patient outcomes Initial therapy of acute graft-versus-host disease with low-dose

  2009cites this paper
• Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report

  2009cites this paper
• Immune Deficits in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients

  2009cites this paper
• Cytomegalovirus vaccination of leukemia and lymphoma patients after allogeneic stem cell transplantation--validation of a peptide vaccine.

  2009cites this paper
• Clinical correlations of human cytomegalovirus strains and viral load in kidney transplant recipients.

  2009cites this paper
• Efficient in vitro priming of tumor- and virus-specific CD8+ T cells with calibrated artifical APCs

  2008cites this paper
• A Modified Peptide Stimulation Method for Efficient Amplification of Cytomegalovirus (CMV)-Specific CTLs

  2008cites this paper
• HUMAN CYTOMEGALOVIRUS: INFECTIONS AND DIAGNOSIS

  2008cites this paper
• Infection in the Hematopoietic Stem Cell Transplant Recipient

  2008cites this paper
• Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real‐world review

  2008cites this paper
• Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

  2008cites this paper
• Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.

  2008cites this paper
• Detection of human cytomegalovirus-specific T lymphocytes in human blood: comparison of two methods.

  2008cites this paper
• CMV-specific T cell therapy.

  2008cites this paper
• Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation

  2007cites this paper
• Adoptive immunotherapy of HCMV infection.

  2007cites this paper
• REVIEW Adoptive immunotherapy of HCMV infection

  2007cites this paper
• Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.

  2007cites this paper
• Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis.

  2007cites this paper
• One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.

  2007cites this paper
• Bone marrow transplantation from a pediatric donor with a high frequency of cytomegalovirus‐specific T‐cells

  2006cites this paper
• Adoptive T lymphocyte therapy to fight cytomegalovirus infection in immunodeficient hosts

  2006cites this paper
• Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes.

  2006cites this paper
• Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation.

  2006cites this paper
• Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation

  2006cites this paper
• Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.

  2006cites this paper
• Critical care considerations of hematopoietic stem cell transplantation

  2006cites this paper
• Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients.

  2006cites this paper
• Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation

  2006cites this paper
• Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

  2005cites this paper
• Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.

  2005cites this paper
• [Infections in bone marrow transplantation].

  2005cites this paper
• Simultaneous generation of cytomegalovirus-specific CD8+ and CD4+ T lymphocytes by use of dendritic cells comodified with pp65 mRNA and pp65 protein.

  2005cites this paper
• Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation.

  2005cites this paper
• Evaluation of pulmonary infiltrates in patients after stem cell transplantation

  2005cites this paper
• Risk-Adapted Preemptive Therapy for Cytomegalovirus Disease after Allogeneic Stem Cell Transplantation: A Single-Center Experience in Korea

  2005cites this paper
• Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation.

  2005cites this paper
• Infecciones en trasplante de médula ósea

  2005cites this paper
• Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

  2004cites this paper
• Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation.

  2004cites this paper
• Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation

  2004influential citation
• Specific infectious complications after stem cell transplantation

  2004cites this paper
• Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes.

  2004cites this paper
• Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy

  2004cites this paper
• High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation

  2004cites this paper
• Generation of Aspergillus- and CMV- specific T-cell responses using autologous fast DC.

  2004cites this paper
• Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen

  2004cites this paper
• Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.

  2004cites this paper
• Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy.

  2004cites this paper
• Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation

  2004cites this paper
• Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants.

  2004cites this paper